Back to News
Market Impact: 0.3
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
Source: globenewswire.com
Healthcare & Biotech
The Explore-CKD trial met its primary endpoint: lorundrostat 25 mg once daily, added to an SGLT2 inhibitor, significantly reduced systolic blood pressure at four weeks. The article provides no effect size or further trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
More News
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- This hospice services stock is outperforming the S&P 500. Jefferies sees more gains ahead
- Biotechs buck a sluggish IPO market, but investors should tread warily
- Waters’ new AI tool targets one of the pharmaceutical industry’s most tedious tasks
- Dassault Systèmes raises 2026 outlook as revenue growth rebound gathers pace
- Needham initiates Clover Health stock with buy on cohort economics